Prostate Cancer | Specialty

The OncLive Prostate Cancer condition center page is a comprehensive resource for clinical news and expert insights on how to approach treatment for patients with nonmetastatic, castration-resistant, or castration-sensitive prostate cancer. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, ongoing research, and treatment advances with androgen receptor inhibitors, PARP inhibitors, and more in prostate cancer.

Dr. Vogelzang Discusses PROSPECT Trial for Prostate Cancer

July 20th 2018

Nicholas J. Vogelzang, MD, site research leader for Comprehensive Cancer Centers of Nevada, member of US Oncology Network, 2018 Giant of Cancer Care

Dr. Hashmi on Immunotherapy in Prostate Cancer

July 18th 2018

Mehmood Hashmi, MD, assistant professor of medicine, University of Kansas Medical Center, discusses the use of immunotherapy in the treatment of patients with prostate cancer.

CTC AR-V7 Assay Shows Promise as Treatment Guide in mCRPC

July 17th 2018

An assay for nuclear-localized androgen receptor splice variant 7 protein in circulating tumor cells identified patients with metastatic castration-resistant prostate cancer who had better outcomes from treatment with taxanes, and those who did better with androgen receptor-signaling inhibitors.

FDA Approves Enzalutamide for Nonmetastatic CRPC

July 14th 2018

The FDA has approved enzalutamide for the treatment of patients with nonmetastatic castration-resistant prostate cancer.

Dr. Gomella on the FDA Approval of Enzalutamide in Nonmetastatic CRPC

July 13th 2018

Leonard Gomella, MD, professor, chair, Department of Urology, director, Sidney Kimmel Cancer Center Network, Thomas Jefferson University Hospital, discusses the FDA approval of enzalutamide (Xtandi) for the treatment of men with nonmetastatic castration-resistant prostate cancer.

Dr. Hashmi on Imaging Modalities in Prostate Cancer

July 13th 2018

Mehmood Hashmi, MD, assistant professor of medicine, University of Kansas Medical Center, discusses imaging modalities in prostate cancer.

Yu Shares Insight on Recent Advances in Castration-Sensitive Prostate Cancer

July 10th 2018

Evan Ya-Wen Yu, MD, discusses the evolution of treatment for patients with castration-sensitive prostate cancer and how he decides between treatment with abiraterone and docetaxel for this population.

Dr. Hashmi on Prostate Cancer Abstracts From the 2018 ASCO Annual Meeting

July 10th 2018

Mehmood Hashmi, MD, assistant professor of medicine, University of Kansas Medical Center, discusses the exciting abstracts in prostate cancer that were presented at the 2018 ASCO Annual Meeting.

Sequencing Challenges Persist in Metastatic Prostate Cancer

July 5th 2018

Scott Samuelson, MD, discusses frontline treatment of patients with prostate cancer and subsequent sequencing.

Dr. Maughan on Enzalutamide Plus Radium-223 in mCRPC

July 4th 2018

Benjamin Maughan, MD, PharmD, instructor, Division of Medical Oncology, Huntsman Cancer Institute, discusses enzalutamide (Xtandi) plus radium-223 (Xofigo) in metastatic castration-resistant prostate cancer.

Study Could Resolve Abiraterone/Docetaxel Debate in Hormone-Sensitive Prostate Cancer

July 2nd 2018

Andy Hahn, MD, discusses the ongoing debate between abiraterone and docetaxel and the optimal patient selection for each agent in patients with metastatic hormone-sensitive prostate cancer.

MRI Combination Techniques Hone Accuracy of Prostate Cancer Diagnosis

July 2nd 2018

Several studies presented at this year’s American Urological Association meeting underscored the value of multiparametric magnetic resonance imaging in the diagnosis and management of prostate cancer.

Dr. Hahn Discusses Abiraterone Versus Docetaxel in Prostate Cancer

June 27th 2018

Andy Hahn, MD, resident, University of Utah School of Medicine, discusses abiraterone acetate (Zytiga) versus docetaxel in the treatment of patients with prostate cancer.

Dr. Yu on Treatment Intensification in Metastatic Castration-Sensitive Prostate Cancer

June 25th 2018

Evan Y. Yu, MD, professor, Department of Medicine, Division of Oncology, University of Washington, Seattle Cancer Care Alliance, discusses treatment intensification in patients with metastatic castration-sensitive prostate cancer.

Study Explores ADT Alternative in Localized Prostate Cancer Recurrence

June 18th 2018

Cryoablation may help men whose prostate cancer recurs after radiation therapy avoid or delay retreatment with androgen deprivation therapy.

Dr. Giri on Genes that Carry a Risk for Prostate Cancer

June 16th 2018

Veda Giri, MD, associate professor, Thomas Jefferson University Hospital, discusses genes that are associated with a risk of developing prostate cancer.

Patients Aged

June 13th 2018

Patients younger than 65 years experienced net cancer costs that were higher for breast, colorectal, lung, and prostate cancer compared with patients who were 65 years and older.

Dr. Samuelson on Frontline Treatment and Subsequent Sequencing in Prostate Cancer

June 12th 2018

Scott Samuelson, MD, medical oncologist, Utah Cancer Specialists, on frontline treatment of patients with prostate cancer and subsequent sequencing.

DNA Repair Defects Are Strong Targets for Therapeutic Development in Prostate Cancer

June 11th 2018

The use of PARP inhibitors in patients with a variety of tumor types is backed by a growing body of research, and there is now strong justification for clinical trials of these agents in patients with prostate cancer.

Moving Radium-223 Forward in the Treatment Timeline for Prostate Cancer With Bone Metastases

June 10th 2018

Moving radium-223 (Xofigo) up in the treatment paradigm for patients with prostate cancer could provide better outcomes and longer survival, according to Richard G. Stock, MD.